title: [Influence of intelligence level of the type I diabetic patients handling hi-tech glycemia monitoring system on the effectiveness of intensive insulin treatment].
abstract: An intensive care system designed and developed in IBBE PAS allows for electronic storage and automatic transmission of BG values and other parameters directly from a patient's BG meter and electronic logbook (Glucometer M+ Bayer) to central clinical computer by telematic connection. Despite effort made to keep the system as simple as possible, its proper handling still requires some additional skills from the patient. Thus, effectiveness of the intensive insulin treatment supported by the system may be influenced by the patient's intelligence level. The aim of this work was to evaluate influence of the intelligence level of type 1 diabetic patients equipped with designed system on effectiveness of a long-term intensive insulin treatment. The study group consisted of 17 type 1 diabetic pregnant women randomly divided in two sub-groups. Eight patients used the transmission system and the remaining 9 patients were treated classically. Patient's intelligence level was assessed according Wechsler scale. Analysis of variance indicated that intelligence level did not influence significantly on average result of the treatment (p > 0.05) in whole study group and in both subgroups. Generally, in patients with lower (93 +/- 2.0) and higher (114.1 +/- 1.2) intelligence level glycemic control indices were found to be similar and did not differ significantly. Performed analysis indicated that the designed system could be properly handled by diabetic patients within wide range of intelligence level. However, despite not statistically significant influence of the patients intelligence level on obtained glycemic control, tendency was observed to obtain better average long-term glycemic control in patients with lower intelligence level using telematic data transmission in comparison with the patients treated in classical way (SDWG = 7.0 +/- 0.4 vs. 8.1 +/- 1.0 mmol/l and J = 30.3 +/- 4.4 vs. 39.0 +/- 12.2).
authors.affiliation: Katedry i Kliniki Gastroenterologii i Chorób Przemiany Materii AM w Warszawie.
authors.forename: J
authors.initials: J
authors.lastname: Krzymień
authors.forename: P
authors.initials: P
authors.lastname: Ladyzyński
authors.forename: J M
authors.initials: JM
authors.lastname: Wójcicki
authors.forename: E
authors.initials: E
authors.lastname: Jóźwicka
authors.forename: J
authors.initials: J
authors.lastname: Blachowicz
authors.forename: H
authors.initials: H
authors.lastname: Mikulicz
authors.forename: K
authors.initials: K
authors.lastname: Czajkowski
authors.forename: E
authors.initials: E
authors.lastname: Janczewska
authors.forename: W
authors.initials: W
authors.lastname: Karnafel
mesh_terms: D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D005260:Female; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D007360:Intelligence; D018670:Monitoring, Ambulatory; D011247:Pregnancy; D016896:Treatment Outcome; D014888:Wechsler Scales
chemical_list: D007328:Insulin